Adverum Biotechnologies presents ADVM-022 preclinical data at ASGCT
Adverum Biotechnologies announced the presentation of additional long-term efficacy data from a preclinical study of ADVM-022 in wet age-related macular degeneration in a poster session today at the ASGCT 21st Annual Meeting in Chicago, IL. "It is exciting to see that a single administration of ADVM-022 has the potential to provide long-term protection against choroidal neovascularization, which is associated with vision loss in wAMD," said Mehdi Gasmi, Ph.D., chief science and technology officer of Adverum Biotechnologies. "Our poster presentation at this year's ASGCT Annual Meeting includes the most robust set of data to date on ADVM-022. Based on the results from these studies and our ongoing Investigational New Drug-enabling studies, we are on track to submit an IND Application for ADVM-022 in the second half of 2018. We are eager to get ADVM-022 into the clinic to advance this gene therapy that may offer convenient, long-term protection for patients living with wAMD."